Bringing the Second COVID-19 Wave Under Control

Bringing the Second COVID-19 Wave Under Control

  • August 7, 2020

While Japan’s coronavirus epidemic appeared to have subsided, it is now roaring back with a vengeance. We asked leading immunologist Miyasaka Masayuki about the extent of the epidemic, his predictions for the future, and what he thinks should be done.

Where Japan Stands

INTERVIEWER  Tokyo and Osaka are seeing record numbers of coronavirus cases. What is your take on the current situation?

MIYASAKA MASAYUKI  There’s no question that we are seeing an uptick in cases. Without knowing the type of virus involved, we can refer to the current outbreak as either a continuation of the first wave, or the beginning of the second wave. The increase in infections has been concentrated in specific entertainment districts, including Tokyo’s Shinjuku and Ikebukuro and Osaka’s Minami, along with their surroundings. These areas harbored a very high number of COVID-19 carriers, and people who frequented these areas have unwittingly taken the virus back to their homes and workplaces, causing it to spread steadily through their communities.

The current spike in infections is by no means restricted to a small geographical area, either—we’re beginning to see outbreaks in surrounding areas as well. And it’s only a matter of time before this outbreak will no longer restricted to young people. While I thought people had learned the lessons of the first wave of infection, some have not, and continue to frequent entertainment districts. That is the problem.

INTERVIEWER  We were told the second wave would not arrive until autumn or winter. It appears to have hit much earlier than expected.

MIYASAKA  Those estimates were merely individual opinions. A lot of people thought the virus’s vulnerability to heat and UV light would keep it at bay in summer, so the second wave would not hit until autumn. While many believed this theory, in the United States we have seen significant outbreaks in summer, in places like Florida.

INTERVIEWER  How is the current outbreak different from the first wave?

MIYASAKA  The circumstances are different this time. The received wisdom, which invoked the concept of herd immunity, held that when a virus-naïve population is exposed to a novel virus, a given percentage of individuals will contract it. Nishiura Hiroshi from Hokkaidō University said that as none of us has immunity to COVID-19, up to 60 percent of the population in Japan could contract the virus. I disagree with his assessment, however.

Immunity levels vary significantly amongst the population, meaning that those with compromised immune systems will contract COVID-19 before their healthier counterparts. The chances of becoming infected after exposure to a given amount of virus are not the same for everyone—those with a high resistance to infection will remain uninfected, eventually halting the spread of infection. Another factor is the public’s knowledge about the virus. During an outbreak, people will maintain social distancing. The theoretical statement that every individual infected goes onto infect 2.5 others assumes no preventative measures are taken—if the population observes social distancing, infections will stop. R0—the basic reproduction number, pronounced “R-nought” or “R-zero”—is actually around 1.25 in Osaka, meaning that if just 20 percent of the population develops immunity, the spread of the virus will be stopped. R0 is approaching 1.25 in Tokyo as well. In other words, we are approaching a state in which the virus is no longer spreading.

Antibodies Are Not Everything

INTERVIEWER Can you briefly explain how immunity works?

MIYASAKA  People talk as if immunity is all about antibodies. There is a theory that the spread of COVID-19 will be stopped when 60% of the population develops immunity. However, this assumes that antibodies are the only things capable of conferring immunity. In fact, exposure to a given amount of COVID-19 will never result in 60 percent of a population becoming infected. Even in Wuhan, the percentage of the population that contracted the virus was no more than 20 percent.

The human immune system is comprised of two layers. The first line of defense is our innate immunity—think of soldiers guarding a gate—which attempts to repel all invaders. If our innate immunity is compromised, our acquired immunity kicks in in the form of lymphocytes. T helper cells, which perform the role of controllers, respond to the infection by instructing B lymphocytes to produce antibodies, which in turn attack the virus. The other avenue of defense involves helper cells creating cytotoxic T lymphocytes, or “killers,” that completely destroy infected cells. While antibodies are only able to kill viruses outside cells, these killer lymphocytes are able to kill viruses inside cells. You need both antibodies and killer lymphocytes to reliably defeat a virus.

INTERVIEWER  So it isn’t just the antibodies—the “soldiers at the gate” are also important.

MIYASAKA  People ignore the fact that some people are able to shake a virus they don’t have antibodies for with their natural immunity alone. Antibody seroprevalence is not the same as the infection rate. In other words, if your innate immunity is robust, you don’t have much to worry about.

It’s likely that the antibodies our bodies make in response to COVID-19 infection will only last for around six months. If this is indeed the case, it will be impossible to attain herd immunity. However, immunity is a two-pronged defense: Some individuals are able to defeat the virus using their innate immunity alone. People shouldn’t get too hung up on antibody seroprevalence rates.

The Risk of an Exponential Spike

INTERVIEWER  Cases are currently on the rise. Do you think the increase can be halted, or could we see a runaway number of cases?

MIYASAKA  While the true number of infections is definitely higher than the number of positive PCR results, I believe the rate of infection will eventually dwindle. That is, we will not see an exponential increase in cases. During the initial wave of infection, we were able to stop the virus from spreading further by restricting our movements by 65 percent. As long as people maintain social distancing, avoid the three Cs, namely closed spaces, crowded places, and close-contact settings, and impose reasonable restrictions on their behavior, we will definitely be able to slow down the spread of the virus. However, if there is not enough testing, we get undetected clusters of infection, and the virus spreads rapidly through the community, as has been the case in Western nations, the epidemic will know no end. Fortunately, the prevalence of the virus in Japan is far lower than in the West.

INTERVIEWER  And yet levels of infection are now higher than the initial peak.

MIYASAKA  The statistics seem worrying if you only focus on the number of infections, but Japan’s prevalence of infection and morbidity rates are far lower than in Western nations. It should be noted, however, that the prediction that the second wave of infection would be only minor has proved to be untrue. While it initially looked like we had defeated the epidemic, this was only the picture on the surface. In reality, there were clusters of infection in Shinjuku, Ikebukuro, and Minami that we didn’t know about. These combined with community contact to create the second wave. By testing exhaustively and reducing cases in these areas, potential causes of infection can be reduced.

What We Should Do

INTERVIEWER  Budget restrictions mean that that it’s more or less impossible to demand that businesses close down. Is enough being done?

MIYASAKA  If each and every one of us can be alert, rather than waiting for local bodies to issue alerts, there is no need to panic. The problem is that people forget to be alert and go out carousing in bars. People will not catch the virus if they follow the rules.

INTERVIEWER  Does a state of emergency need to be declared?

MIYASAKA  No. Declaring a state of emergency does have some value because it forces people to moderate their behavior. However, issuing another state of emergency now would have grave consequences for the economy. Now is not the time to declare an emergency. As long as individuals remain alert, the virus will not spread that easily.

INTERVIEWER  The government has chosen the present time to launch its “Go To” travel campaign, although it has excluded Tokyo and its residents from participation. Should we be worried?

MIYASAKA  We have known all along that increased movement by the population would result in the virus being passed on again. Increased movement due to the campaign might or might not increase infections, although as long as travelers modify their behavior as required, the virus will not be passed on so easily. There is no need to order businesses or schools to close, with the exception of a few special industries, as long as individuals remain alert.

INTERVIEWER  Many more people are working from home now. Is remote working an effective strategy for fighting COVID-19?

MIYASAKA  Working from home obviously helps prevent the spread of infection, although just because you take the train to work does not automatically mean you will catch coronavirus. When we speak, a mist of droplets is propagated 2 meters from our mouths, but this volume can be cut by 90 percent by wearing a mask. While the micro droplets that waft out from the sides of our nose and mouth linger in the air for 10 to 15 minutes, they can be dispersed with fans and removed with ventilation. Packed trains are obviously not good, but people don’t need to be overly worried just because their train is a little full. Avoiding rush hour is also an effective strategy. The worst thing is to become so risk-averse that you can’t do anything.

Why Random Testing Won’t Work

INTERVIEWER  So a primary cause of the continuation of this epidemic is entertainment districts, and that if countermeasures are taken people can carry on as normal?

MIYASAKA  Effectively, yes. By no means do I believe entertainment districts are the only places people are becoming infected, though, as we know the virus has spread to surrounding areas as well. However, as long as we all observe social distancing, wear masks, and take precautions, the virus will not spread any further. Then it just becomes a matter of testing exhaustively in places with a high concentration of cases.

INTERVIEWER  I guess we need to increase PCR testing so that we can identify places with high concentrations of the virus.

MIYASAKA  Far too few PCR tests are being performed. Capacity needs to be boosted by a factor of ten or twenty. That said, sentinel, or random, testing will not achieve anything. In Tokyo, for instance, Shinjuku, Ikebukuro, and the surrounding areas need to be tested extensively. We need to make much more use of PCR testing to determine routes of transmission. I’m not saying we need to test everyone—rather, that we have to make a concerted effort in areas where it’s warranted. PCR testing is the most important part of that approach.

A PCR test is like a snapshot. You might be negative today, but that’s not to say you won’t be positive tomorrow. Because COVID-19 has a five-day incubation period, a negative PCR test result does not guarantee you are not infected. We need to perform frequent, exhaustive testing of those populations that need to be tested. Many people in Shinjuku started interacting with others again after a negative test result, only to later find that they were positive. It is therefore important to perform testing frequently. It is impossible to test everyone in the population.

As I have been saying all along, rather than relying on PCR testing, we need to make more use of faster, cheaper methods of detecting viral antigens. Tests can be performed on saliva samples, removing the risk of catching the virus at the test facility. While the saliva antigen test is slightly less sensitive than the PCR method, it does have the advantage of being more sensitive to individuals who shed larger amounts of virus. Frequent, repeated viral antigen screening is a much more useful way to prevent the spread of the virus than one-off PCR testing.

The Benefits of Vaccination

INTERVIEWER  There is still no vaccine or drug that can fight SARS-CoV-2. Is there a way of boosting our immunity to defend against COVID-19?

MIYASAKA  It may be possible for people to eliminate the virus by leveraging their innate immunity. Recent studies show that innate immunity can be trained. We often hear about BCG, a bovine pathogen that also protects humans from tuberculosis. BCG boosts your innate immunity by training it, thereby making your acquired immunity more easily triggered. A look at data from several dozen countries shows a clear trend to lower tuberculosis mortality and morbidity in countries that have embarked on widespread administration of BCG. There are, of course, exceptions. However, the amount of BCG that can be produced for pediatric vaccines is limited, and the vaccine is not produced for adult use.

In Japan, those in their fifties and sixties have gone over 30 years without a vaccination. Conversely, young children are immunized with nearly ten different vaccines, resulting in very low morbidity rates. Children are vaccinated annually, each time stimulating their innate and acquired immunity. This may explain the low incidence of COVID-19 in children and young people. Senior citizens, on the other hand, have not received an immunological challenge since they were last vaccinated decades earlier, and therefore their trained immunity is no longer effective. If senior citizens are happy to endure the inconvenience of being revaccinated against streptococcus pneumonia and influenza, they may receive unexpected benefits.

Differences Between Asia and the West

INTERVIEWER  Why are there far fewer infections and deaths in Japan and other parts of Asia than there are in the West?

MIYASAKA  There are many factors involved. Genes are part of it, as is the lack of kissing, hugging, and shaking hands in our culture, and the practice of removing one’s shoes indoors. But there’s something else that makes Asians less likely to be infected. BCG is part of the story, but it’s not everything.

One factor is region-specific infections. There are four varieties of nasal cold virus in the common human coronavirus family, which appear in frequent outbreaks in Japanese schools. Around 15 percent of common colds are caused by a common human coronavirus. It is possible that exposure to these viruses for some reason makes you less susceptible to COVID-19. Exposure to region-specific infections boosts your innate immunity, and to an extent stimulates acquired immunity as well. A strain specific to Asia would explain the disparity, although at the moment we don’t know if such a strain exists.

(Originally published in Japanese. Banner photo: Shinjuku Mayor Yoshizumi Ken’ichi, second from left, patrols host clubs in the city’s Kabukichō entertainment district. © Jiji.)

S.I. rapper launches fresh juice business amid coronavirus outbreak

S.I. rapper launches fresh juice business amid coronavirus outbreak

  • August 6, 2020

STATEN ISLAND, N.Y. — Caitlin Hawkins, known as Prema777 in the music world, needed to find a way to make a living when the coronavirus (COVID-19) forced a global lockdown.

Soon after the New Springville resident learned how the virus was affecting those with underlying health conditions, Hawkins, who is the mother of a 1-year-old son and is pregnant with her second child, said she wanted to come up with a way to keep people healthy.

And with her music on hold due to the health crisis, she said was looking for a way to earn money.

That’s when Hawkins — known for her poetic and melodic style of rap music, and her latest album, “Take Flight,” recorded at the North Shore studio House of Dreams in Clifton — created imunaTea, a fresh juice delivery service.

“I call it imunaTea because I started it with the intent of helping people build their immune system through the pandemic. …My intention is to build something for myself and my family by helping others and giving back to the community. Health is wealth and should be affordable and accessible for everyone,” said Hawkins, who has formerly worked in the hospitality industry as a server and bartender.

A CREATIVE OUTLET

While music is her first outlet for creativity, she said her new business is also one that allows her to create something that can help others.

“Music is my therapy and first love. … I love rapping and I love performing ….Music has gotten me through challenging times and always inspires me to reinvent. I heal and help through music, and now it’s just about expanding that same concept through my juicing creativity,” said Hawkins.

“When you take care of yourself, you feel good. And when you help other people, it’s inspiring. That’s what I get from my music; I want to help people. Ultimately, my goal is to send a message to people to give them hope,” she added.

With a second child due in October, Hawkins said she wants to take the time to set a “good intention,” and build a business for which she could be proud.

“I’m a mother and business women who always wants to be busy,” she said. “I want to show my children that you have to work during hard times…. Plus, the business was one I could do with my son. I could put a mask on and use hand sanitizer, and put him in the car and make my deliveries.”

THE JUICES

Hawkins said she focuses on three main juices:

Energy-boosting shot: Made of a turmeric, ginger, orange and black pepper. “Turmeric has an immense amount of healing properties in it. It’s an anti-inflammatory. It fights diseases,” Hawkins explained. “These shots make you feel fresh and are great to start your day.”

Boost juice: A beverage made of orange, lemon, carrot, green apple, turmeric and ginger. “This is a tasty drink to make you feel good and to boost your immune system,” said Hawkins. “It’s like a super fresh orange juice with a little bit of earthiness to it.”

Teatox: “This is a green juice,” she said, noting it’s made of greens, cucumber, honeydew, green apple and Greek yogurt.

BUILDING A COMMUNITY

Hawkins said her long-term goal is to build an “imunaTea community.”

“I’d like to create a space that inspires success stories in exchange for free knowledge on holistic and homeopathy remedies. Anyone and everyone will be welcome to join,” she said.

IMUNATEA AT A GLANCE

Website: https://imunatea.bigcartel.com/

Facebook: https://www.facebook.com/imun.juice.boost/

*** CLICK HERE FOR COMPLETE COVERAGE OF CORONAVIRUS IN NEW YORK***

New Businesses in Focus is a weekly column that relates the stories of new Staten Island businesses owners.

If you have a new business on Staten Island, e-mail porpora@siadvance.com.

REALTED COLUMNS

Family opens chicken restaurant just as coronavirus hit NYC

Father-son team opens barbershop 3 months before coronavirus outbreak

Old fashioned ‘head shop’ expands during coronavirus pandemic

The Beauty Suite offering virtual makeup tutorials

Despite losing family matriarch to coronavirus, father/son team opens new Italian restaurant on Bay St.

Coronavirus: Flagship Brewery delivers craft beer to your doorstep

Coronavirus: Schools are virtual, and so is this tutor

Coronavirus: Family-owned auto body shop offers free mobile estimates

Coronavirus: Staten Island radio DJs spin music from home

FOLLOW TRACEY PORPORA ON FACEBOOK and TWITTER

Novavax (NVAX) Stock Fluctuates After Early Covid Data Shows Promise

Novavax (NVAX) Stock Fluctuates After Early Covid Data Shows Promise

  • August 4, 2020
US-VIRUS-HEALTH

Photographer: Andrew Caballero-Reynolds/AFP via Getty Images

Novavax Inc. shares saw huge swings in extended trading as investors took a critical eye to early data on its experimental vaccine for Covid-19 following a 3,800-percent rally in the stock this year.

The shares briefly fell as much as 34% postmarket on Tuesday, before paring the decline. The two-injection regimen when administered concurrently with Novavax’s immune-boosting technology generated antibody responses that were four times higher than those seen in people who had recovered from the disease. Some of the healthy adults in the study experienced side effects including fever, headache and fatigue.

Confusion over the vaccine’s safety data arose after a media report incorrectly said trial participants were hospitalized with severe reactions. The vaccine appeared safe in the more than 100 patients who received it, according to the company. Reactions to the shots were generally mild, lasting two days or less. One patient getting the vaccine had a mild skin infection that was determined not to be related to the shot.

Gregory Glenn, Novavax’s head of research and development, said adverse events were “sporadic” and spread across placebo as well as vaccinated patients in the study.

Curtis Park Pharmacy To Open Despite Other Coronavirus Business Closures – CBS Sacramento

Curtis Park Pharmacy To Open Despite Other Coronavirus Business Closures – Good Day Sacramento

  • August 1, 2020

SACRAMENTO (CBS13) – Amid several businesses closing their doors due to the coronavirus pandemic, one Sacramento pharmacy is soon opening theirs.

“The reason this is called Ten Acres Pharmacy is because in 1918, where this is located, there were 10-acre tracts,” said owner Sonya Frausto.

Frausto is putting the finishing touches on her new business in Curtis Park. She had hoped to open in May, but COVID-19 slowed construction. So she has been stocking up on products.

“On local products, small businesses, women-owned businesses, minority-owned businesses, so a lot of the products you see that are kind of unique that you don’t see,” she said.

Frausto decided to make the move after being laid off from a larger pharmacy. She wanted her business to focus on functional medicine, which she said helps patients restore their health by identifying the root causes of what ails them.

She has teamed up with a local doctor who specializes in that.

“We talked about partnerships and ways we can work together to bring information to our local community about how they can work and live healthier through supplements, through taking care of themselves, knowledge and education,” Frausto said.

Frausto said it’s been a challenge opening her business during the pandemic because it’s hard to get some products, but she sees it as an opportunity.

“For people to walk in and ask the questions they want to ask, be able to get the products they want – masks, hand sanitizers, basic things like ibuprofen or hopefully a vitamin to help them feel better or boost their immune system – those are all important things,” she said.

She said she knows her location on Freeport Boulevard is close to several other mom and pop type businesses will serve the neighborhood, especially now.

“This is a wonderful addition to our neighborhood,” said Eileen Sargent, who lives in the area. “You can walk to the pharmacy.”

Frausto said she sees her personalized service and supplies as just what the doctor ordered to fill a need in the community.

Curtis Park Pharmacy To Open Despite Other Coronavirus Business Closures – CBS Sacramento

Curtis Park Pharmacy To Open Despite Other Coronavirus Business Closures – CBS Sacramento

  • August 1, 2020

SACRAMENTO (CBS13) – Amid several businesses closing their doors due to the coronavirus pandemic, one Sacramento pharmacy is soon opening theirs.

“The reason this is called Ten Acres Pharmacy is because in 1918, where this is located, there were 10-acre tracts,” said owner Sonya Frausto.

Frausto is putting the finishing touches on her new business in Curtis Park. She had hoped to open in May, but COVID-19 slowed construction. So she has been stocking up on products.

“On local products, small businesses, women-owned businesses, minority-owned businesses, so a lot of the products you see that are kind of unique that you don’t see,” she said.

Frausto decided to make the move after being laid off from a larger pharmacy. She wanted her business to focus on functional medicine, which she said helps patients restore their health by identifying the root causes of what ails them.

She has teamed up with a local doctor who specializes in that.

“We talked about partnerships and ways we can work together to bring information to our local community about how they can work and live healthier through supplements, through taking care of themselves, knowledge and education,” Frausto said.

Frausto said it’s been a challenge opening her business during the pandemic because it’s hard to get some products, but she sees it as an opportunity.

“For people to walk in and ask the questions they want to ask, be able to get the products they want – masks, hand sanitizers, basic things like ibuprofen or hopefully a vitamin to help them feel better or boost their immune system – those are all important things,” she said.

She said she knows her location on Freeport Boulevard is close to several other mom and pop type businesses will serve the neighborhood, especially now.

“This is a wonderful addition to our neighborhood,” said Eileen Sargent, who lives in the area. “You can walk to the pharmacy.”

Frausto said she sees her personalized service and supplies as just what the doctor ordered to fill a need in the community.

Single Vitamins see 166% Growth as Consumers Look to Boost Immunity During COVID-19 Lockdown - ResearchAndMarkets.com | Business

NeoImmuneTech Announces FDA Approval to Proceed with Second Study of NT-I7 (efineptakin alfa) in Adult COVID-19 Patients | Business

  • July 28, 2020

ROCKVILLE, Md.–(BUSINESS WIRE)–Jul 27, 2020–

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it has received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) for the second study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, for the treatment of COVID-19. The investigator-initiated Phase 1 trial is being conducted by Jian Li Campian, M.D., Ph.D. of Washington University School of Medicine, St. Louis. The trial is a multi-center, double-blind, randomized, placebo-controlled study that will evaluate the safety and efficacy of NT-I7 in adult COVID-19 patients.

IL-7 is an important growth factor for the immune system, the release of which induces the development, proliferation, and persistence of naïve and memory T cells. IL-7 has been shown to restore lymphocyte count, enhance anti-viral T cell response, reduce T cell exhaustion and death, and thereby potentially improve clinical outcomes in patients with COVID-19, where low lymphocyte count strongly correlates with poor prognosis. NT-I7 is the only clinical-stage long-acting IL-7, and has demonstrated in multiple clinical trials to restore lymphocyte count, including naïve and memory T cells, and exhibits a well-tolerated safety profile.

“Treatments that harness and enhance the immune system, helping it fight diseases such as cancer and infectious diseases, hold promise in treating a viral infection such as COVID-19, where the immune system is extremely burdened and exhausted,” said Dr. Campian. “As a T-cell amplifier, NT-I7 is designed to boost the adaptive immune response, which is crucial for the clearance of the virus in COVID-19. I look forward to evaluating this therapeutic candidate in patients with COVID-19.”

“Continuing on our mission to improve patient lives, NeoImmuneTech is very pleased to have received FDA clearance to begin a second trial studying NT-I7 as a potential immune enhancer for adult COVID-19 patients. The two trials will complement each other and speed up enrollment as well as increase the number of patients,” said NgocDiep Le, M.D., Ph.D., Executive Vice President and Chief Medical Officer of NeoImmuneTech. “Since lymphopenia is a hallmark of COVID-19, patients with weakened immune systems are at particularly high risk for a serious infection of COVID-19, and subsequently have unfavorable clinical outcomes, including death. NeoImmuneTech hopes that NT-I7 could help to prevent the progression to severe COVID-19 and ultimately improve clinical outcomes for patients affected by this pandemic.”

About NT-I7

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T-cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T-cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200727005123/en/

CONTACT: MacDougall

Shai Biran, Ph.D.

781-235-3060

sbiran@macbiocom.com

KEYWORD: MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH FDA INFECTIOUS DISEASES GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: NeoImmuneTech, Inc.

Copyright Business Wire 2020.

PUB: 07/27/2020 07:00 AM/DISC: 07/27/2020 07:00 AM

http://www.businesswire.com/news/home/20200727005123/en

Copyright Business Wire 2020.

California Cherry Harvest Signals A Sweet Way to Boost Your Mood | Coronavirus

NeoImmuneTech Announces FDA Approval to Proceed with Second Study of NT-I7 (efineptakin alfa) in Adult COVID-19 Patients | Coronavirus

  • July 27, 2020

ROCKVILLE, Md.–(BUSINESS WIRE)–Jul 27, 2020–

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it has received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) for the second study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, for the treatment of COVID-19. The investigator-initiated Phase 1 trial is being conducted by Jian Li Campian, M.D., Ph.D. of Washington University School of Medicine, St. Louis. The trial is a multi-center, double-blind, randomized, placebo-controlled study that will evaluate the safety and efficacy of NT-I7 in adult COVID-19 patients.

IL-7 is an important growth factor for the immune system, the release of which induces the development, proliferation, and persistence of naïve and memory T cells. IL-7 has been shown to restore lymphocyte count, enhance anti-viral T cell response, reduce T cell exhaustion and death, and thereby potentially improve clinical outcomes in patients with COVID-19, where low lymphocyte count strongly correlates with poor prognosis. NT-I7 is the only clinical-stage long-acting IL-7, and has demonstrated in multiple clinical trials to restore lymphocyte count, including naïve and memory T cells, and exhibits a well-tolerated safety profile.

“Treatments that harness and enhance the immune system, helping it fight diseases such as cancer and infectious diseases, hold promise in treating a viral infection such as COVID-19, where the immune system is extremely burdened and exhausted,” said Dr. Campian. “As a T-cell amplifier, NT-I7 is designed to boost the adaptive immune response, which is crucial for the clearance of the virus in COVID-19. I look forward to evaluating this therapeutic candidate in patients with COVID-19.”

“Continuing on our mission to improve patient lives, NeoImmuneTech is very pleased to have received FDA clearance to begin a second trial studying NT-I7 as a potential immune enhancer for adult COVID-19 patients. The two trials will complement each other and speed up enrollment as well as increase the number of patients,” said NgocDiep Le, M.D., Ph.D., Executive Vice President and Chief Medical Officer of NeoImmuneTech. “Since lymphopenia is a hallmark of COVID-19, patients with weakened immune systems are at particularly high risk for a serious infection of COVID-19, and subsequently have unfavorable clinical outcomes, including death. NeoImmuneTech hopes that NT-I7 could help to prevent the progression to severe COVID-19 and ultimately improve clinical outcomes for patients affected by this pandemic.”

About NT-I7

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T-cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T-cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200727005123/en/

CONTACT: MacDougall

Shai Biran, Ph.D.

781-235-3060

sbiran@macbiocom.com

KEYWORD: MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH FDA INFECTIOUS DISEASES GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: NeoImmuneTech, Inc.

Copyright Business Wire 2020.

PUB: 07/27/2020 07:00 AM/DISC: 07/27/2020 07:00 AM

http://www.businesswire.com/news/home/20200727005123/en

Copyright Business Wire 2020.

Immune Elements Review: Detailed Report with Shocking Facts Revealed

Cordyceps Sinensis Extract Market Size and Share to Project Lucrative CAGR By 2020 | Future Growth Trends, Key Players Profile, Business Insights, Overview, Growth Projection and Global Market Analysis By 2026

  • July 24, 2020

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request Sample

Cordyceps sinensis, also known as ophiocordyceps sinensis, is combination of parasitic fungus species and dead caterpillars that offer several potential health applications. It has been described as a medicine in old Chinese medical books and Tibetan medicine for the treatment of around 21 ailments such as low immunity and high blood pressure. Cordyceps spores grows inside the caterpillar’s body and infects it. It gradually degrades the living larva and mummifies it in the soil and a cordyceps stem emerges from head part of the caterpillar.

Some of the active ingredients in cordyceps sinensis extract include, cordycepin, adenosine, exopolysaccharide fraction (EPSF), cordyglucans, and monosaccharide saponin. Several research studies and clinical trials have concluded that cordyceps sinensis extract can aid in the treatment of several diseases such as diabetes, high cholesterol, and hypertension. Cordyceps sinensis also increases immunity and can relive stress, thereby finding application in the tenement of stress related disorders.

Cordyceps sinensis is available in various forms such as tablet, powder, and capsule. Several regulatory bodies worldwide such as the U.S. FDA has approved the use of cordyceps sinensis extract as dietary supplement.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1983

Cordyceps Sinensis Extract Market- Market Dynamics

Cordyceps sinensis has several medicinal properties such as cholesterol reduction, stimulation of the immune system, faster recovery from bronchitis and other respiratory diseases, and boosting efficiency of the circulatory system. It can also be used in the treatment of cancer and liver-associated diseases as it offers fast recovery from chemotherapy and improves libido, a general body adaptogen (enhanced body energy and strength)

High prevalence of chronic diseases such as cardiovascular disease, cancer, diabetes, and respiratory diseases is expected to aid in growth of the cordyceps sinensis extract market. For instance, according to the World Health Organization’s statistics in 2018, non-communicable diseases are responsible for over 41 million deaths, annually, which is equivalent to 71% of all deaths, worldwide. Furthermore, according to the same source, cardiovascular diseases causes over 17.9 million deaths, annually, followed by cancer (9.0 million), respiratory diseases (3.9million), and diabetes (1.6 million), respectively.

High prevalence of autoimmune and stress related disorders is also expected to boost the market growth, especially in developed regions such as North America and Europe. For instance, according to the American Autoimmune Related Disease Association, more than 50 million people in the U.S. were affected by autoimmune disease in 2017.

However, high cost of cordyceps sinensis extracts is expected to hamper the market growth. Moreover, absence of solid proof of efficiency of the extract in the treatment of several diseases such as cancer and diabetes may also restrict the market growth. Increasing the artificial cultivation of cordyceps sinensis species is filled with several challenges. High cost of cordyceps sinensis in the international market often leads to malpractice of adulteration and substitution in the extracts.

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1983

Cordyceps Sinensis Extract Market- Regional Insights

On the basis of region, the global cordyceps sinensis extract market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the market during the forecast period, followed by Europe. The market in North America is driven by increasing prevalence of chronic diseases in the U.S. For instance, according to the Centers for Disease Control and Prevention, seven of the top ten causes of deaths in the U.S. in 2014 were chronic diseases, heart diseases, and cancer, which together accounted for over 46% of the deaths in the country. Moreover, high prevalence of mental disorders is also expected to contribute to the market growth as cordyceps sinensis extracts can reduce the symptoms related to mental disorders. For instance, according to Anxiety and Depression Association of America in 2017, anxiety disorders are the most common mental illness in the U.S., affecting around 40 million adults aged 18 years and above, or 18.1% of the population, annually. However, only 36.9% of those suffering from anxiety receive treatment.

The market in Asia Pacific is expected to witness significant growth over the forecast period as the region is major producer of cordyceps sinensis extracts, especially in China. For instance, according to the data presented by the Ministry of Agriculture and Rural Affairs of the People’s Republic of China in 2011, China has 200,000 kg of cordyceps sinensis and 120,000 kg was harvested. Qinghai and Tibet regions export around 20,000 kg of cordyceps sinensis to countries such as the U.S., Japan, Korea, Hong Kong, Macao, and Taiwan and some countries in Europe and South East Asia with an annual export of over 20,000 kg.  Moreover, increasing prevalence of chronic diseases and preference for traditional medicines for the treatment of such diseases in the region is expected to boost growth of the cordyceps sinensis extract market.

Cordyceps Sinensis Extract Market- Competitive Landscape

Key players operating in the global cordyceps sinensis market include, Naturalin, Active Organics, Quyuan sunnycare Inc., Kangzhou, HERBSINO, SOST, Health Choice Limited, Zhongke Group, and Nutra Green.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1983

Cordyceps Sinensis Extract Market – Market Taxonomy

On the basis of dosage form, the global cordyceps sinensis extract market is segmented into –

On the basis of application, the global cordyceps sinensis extract market is segmented into -:

  • Dietary supplement
  • Medicinal use
  • Others

On the basis of distribution channel, the global cordyceps sinensis extract market is segmented into -:

  • Retail Pharmacy
  • Online Pharmacy

On the basis of geography, the global cordyceps sinensis extract market is segmented into-:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Increased Health Consciousness As A Result Of The Coronavirus Is Fueling Demand For Immunity Boosting Food Products

Increased Health Consciousness As A Result Of The Coronavirus Is Fueling Demand For Immunity Boosting Food Products – Press Release

  • July 22, 2020
Increased Health Consciousness As A Result Of The Coronavirus Is Fueling Demand For Immunity Boosting Food Products

“Immunity Boosting Food Products Market Global Report 2020-30: Covid 19 Implications And Growth”

The Business Research Company’s Immunity Boosting Food Products Market Global Report 2020-30: Covid 19 Implications And Growth, Segments Covered: 1) By Product Type: Herbs & Spices, Nuts & Seeds, Fruits & Vegetables, Dairy-Based Products, Probiotics And Prebiotics, Others 2) By Form: Tablets, Capsules, Powder, Liquid, Others 3) By Distribution Channel: Store-Based, Non-Store-Based

The global immunity boosting food products market size is expected to grow from $16.31 billion in 2019 to $22.76 billion in 2020 at a compound annual growth rate (CAGR) of 39.6%. The exponential growth is mainly due to the outbreak of COVID-19 that raised awareness about boosting immunity in the human body, to protect from being infected by the virus. The market is then expected to reach $24.02 billion in 2023 at a CAGR of 1.81%.

The increasing consciousness about health and fitness to live a healthier lifestyle will drive the immunity-boosting food products market. According to the Global Wellness Institute, in 2018, the global wellness market was valued at $4.5 trillion. According to the IHRSA (International Health, Racquet & Sportsclub Association), the health and fitness industry in the U.S. was valued at $30 billion in 2018. It has been growing by at least 3-4% annually for the last ten years. Also, the World Health Organization has declared the novel coronavirus (Covid-19) as a pandemic. A strong immune system is a key factor in the treatment of COVID 19 patients. This has resulted in an increase in the demand for immunity boosting products, thereby driving the immunity-boosting food products market growth.

According to immunity boosting food products market trends, instant immunity booster products are increasingly being used to boost immune function, which is used when under stress in the modern world. For instance, in January 2020, ZAND, the natural lozenge brand in health food stores known for herbal-based immune support, launched the first rapid immunity product, Immune Fast. This breakthrough new supplement delivers clinically approved immune support whenever and wherever- at work, the airport, school, large gatherings, etc. Thus, it is used on the spot to boost the immune system within two hours.

The high cost of raw materials and lack of awareness among people about the benefits of immunity-boosting products is hampering the growth of the immunity booster food products market. Nutrition care, which is an essential element of preventive health care, is simultaneously experiencing a major evolution in highly populous countries like India. There is a lack of awareness about immunity boosting food products in the swiftly growing middle-class population. On the other hand, the high cost of raw materials used in the manufacturing of immunity-boosting food products has a great impact on the price of the final product, which may render them a practical option only for the urban and rich population, thereby limiting the market growth.

The immunity boosting food products global market report is segmented by product type into herbs & spices, nuts & seeds, fruits & vegetables, dairy-based products, probiotics and prebiotics, and others. By form, the market is segmented into tablets, capsules, powder, liquid, and others. By distribution channel, it is segmented into store-based, and non-store-based.

Major players in the immunity boosting food products market are Danone SA, Nestle S.A., Blue Diamond Growers, Diamond Foods, LLC., Dole Food Company, Inc., Pinnacle Foods Corp., Olam International, Hines Nut Company, Fonterra Group Cooperative Limited, and Associated British Foods PLC.

Here Is A List Of Similar Reports By The Business Research Company:

Functional Food Market Global Report 2020-30: Covid 19 Growth And Change

Organic Food Global Market Report 2020

Gluten Free Food Market Global Report 2020-30: Covid 19 Growth And Change

Functional Beverages Market Global Report 2020-30: Covid 19 Growth And Change

The World’s Most Comprehensive Database

The Business Research Company’s flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_Info

Media Contact
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
Address:
City: London
State: Greater London
Country: United Kingdom
Website: https://www.thebusinessresearchcompany.com/

Kanavance CBD Oil Reviews : Kanavance CBD UK Price Cost

Aviation Business Center Earns Leed Gold

  • July 21, 2020

The U.S. Green Building Council has recognized the City of Scottsdale’s Aviation Business Center, 15000 N. Airport Dr, with the LEED (Leadership in Energy and Environmental Design) Gold certification. The award recognizes the project for its sustainable, green building qualities.

The Aviation Business Center is a modern two-story 23,250 SF steel building featuring glass facades, wood designer elements and an open design. It serves as the hub for the aviation administration offices, U.S. Customs and Border Protection office, leased office space, public meeting rooms, outdoor plaza, on-site restaurant and a veteran’s memorial. (Photo: Aviation Business Center by Kyle Zirkus. Design and Construction team included: Aviation Department staff, Mead & Hunt, DWL Architects + Planners and JE Dunn Construction)

During the design, staff and the architects worked hard to achieve LEED Gold standards while maintaining the vision, budget and schedule for the project. The building was designed to conserve resources and reduce energy consumption.

“We are proud of achieving gold-level certification,” says Aviation Director Gary P. Mascaro. “The goal from the start was to build to a high level of sustainable standards without sacrificing on design.”

The project employed many sustainable strategies including:

  • Roofing does not contribute to heat island effect
  • Low flow plumbing fixtures
  • No CFC based refrigerants
  • Building materials that were sourced locally were given preference
  • Building materials with a high recycled content were given preference
  • Materials and products with low or no volatile organic compounds (VOC’s) were used in the interior
  • Development of the site in a way that maximizes open space
  • Utilization of roofing that minimizes heat island effect
  • Onsite renewable energy – Photo-voltaic
  • Responsible management of construction waste
  • Wood products were harvested sustainably
  • Bicycle racks

Most new city buildings strive to be built to LEED Gold standards per Section 2 of Resolution No. 6644. The City of Scottsdale has 14 LEED certified buildings, including four Platinum and now five Gold buildings.

The LEED Green Building Rating System™ is the nationally accepted benchmark for the design, construction, and operation of high-performance green buildings. There are four demanding levels of certification (from lowest to highest): Certified, Silver, Gold and Platinum.

Do NOT follow this link or you will be banned from the site!